Last reviewed · How we verify

NCT03957083

Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI ≥ 40kg/m2

Completed NA Last updated 6 February 2020
What this trial tests

NA trial testing Oxytocin in Postpartum Hemorrhage in 30 participants. Completed in 4 February 2020.

Timeline
26 June 2019
Primary endpoint
3 February 2020
4 February 2020

Quick facts

Lead sponsorSamuel Lunenfeld Research Institute, Mount Sinai Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment30
Start date26 June 2019
Primary completion3 February 2020
Estimated completion4 February 2020
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Who can join

Adults 18 to 50, female only, with Postpartum Hemorrhage or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postpartum hemorrhage (PPH) due to uterine atony is a major cause of maternal morbidity and mortality. Uterotonic drugs are used to improve the muscle tone of the uterus after birth, and these are effective at reducing the incidence of PPH. Oxytocin is the most commonly used uterotonic drug to prevent and treat PPH. Large doses of this drug are asociated with adverse effects like low blood pressure, nausea, vomiting, abnormal heart rhythms and changes on ECG. Various international bodies recommend varying and high doses of oxytocin in elective cesarean sections. A study performed at Mount Sinai Hospital showed that a much smaller dose of oxytocin is required (ED95 being 0.35IU). However, most of the women included in this study were below a body mass index (BMI) of 40kg/m2. The investigators seek to find the best dose for patients with a BMI\>40kg/m2, as a higher dose may be needed in this population to contract the uterus adequately.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Oxytocin

Trials testing the same drug.

Other recruiting trials for Postpartum Hemorrhage

Currently open trials in the same condition.

Other Samuel Lunenfeld Research Institute, Mount Sinai Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03957083.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing